<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33654312</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-0048</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature reviews. Neuroscience</Title><ISOAbbreviation>Nat Rev Neurosci</ISOAbbreviation></Journal><ArticleTitle>Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation.</ArticleTitle><Pagination><StartPage>197</StartPage><EndPage>208</EndPage><MedlinePgn>197-208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41583-021-00431-1</ELocationID><Abstract><AbstractText>Cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP43; also known as TARDBP or TDP-43) is a key pathological feature of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP43 typically resides in the nucleus but can shuttle between the nucleus and the cytoplasm to exert its multiple functions, which include regulation of the splicing, trafficking and stabilization of RNA. Cytoplasmic mislocalization and nuclear loss of TDP43 have both been associated with ALS and FTD, suggesting that calibrated levels and correct localization of TDP43 - achieved through an autoregulatory loop and tightly controlled nucleocytoplasmic transport - safeguard its normal function. Furthermore, TDP43 can undergo phase transitions, including its dispersion into liquid droplets and its accumulation into irreversible cytoplasmic aggregates. Thus, autoregulation, nucleocytoplasmic transport and phase transition are all part of an intrinsic control system regulating the physiological levels and localization of TDP43, and together are essential for the cellular homeostasis that is affected in neurodegenerative disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tziortzouda</LastName><ForeName>Paraskevi</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6969-8158</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Den Bosch</LastName><ForeName>Ludo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0104-4067</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium. ludo.vandenbosch@kuleuven.vib.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, VIB-KU Leuven Center for Brain &amp; Disease Research, Leuven, Belgium. ludo.vandenbosch@kuleuven.vib.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirth</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-8581-9450</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. frank.hirth@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HIRTH/OCT13/868-792</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0714</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>HIRTH/OCT16/890-792</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701498</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010666/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurosci</MedlineTA><NlmUniqueID>100962781</NlmUniqueID><ISSNLinking>1471-003X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2021 Aug;22(8):514</RefSource><PMID Version="1">34103710</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2021 Aug;22(8):515</RefSource><PMID Version="1">34103711</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>3</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33654312</ArticleId><ArticleId IdType="doi">10.1038/s41583-021-00431-1</ArticleId><ArticleId IdType="pii">10.1038/s41583-021-00431-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ou, S. H., Wu, F., Harrich, D., Garc&#xed;a-Mart&#xed;nez, L. F. &amp; Gaynor, R. B. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol. 69, 3584&#x2013;3596 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7745706</ArticleId><ArticleId IdType="pmc">189073</ArticleId><ArticleId IdType="doi">10.1128/jvi.69.6.3584-3596.1995</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti, E. et al. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 20, 1774&#x2013;1784 (2001). This paper was the first to describe splicing regulation as a major function of TDP43 activity.</Citation><ArticleIdList><ArticleId IdType="pubmed">11285240</ArticleId><ArticleId IdType="pmc">145463</ArticleId><ArticleId IdType="doi">10.1093/emboj/20.7.1774</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId><ArticleId IdType="doi">10.1126/science.1134108</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602&#x2013;611 (2006). Together with Neumann et al. (2006), this paper identifies TDP43 as the main component of proteinaceous inclusions in ALS and FTD, and describes nuclear depletion and cytoplasmic accumulation as major hallmarks of disease.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyburn, L. &amp; Moussa, C. E.-H. TDP-43 in the spectrum of MND-FTLD pathologies. Mol. Cell. Neurosci. 83, 46&#x2013;54 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28687523</ArticleId><ArticleId IdType="pmc">5581706</ArticleId><ArticleId IdType="doi">10.1016/j.mcn.2017.07.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht, W. &amp; Philips, T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14, 248&#x2013;264 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23463272</ArticleId><ArticleId IdType="doi">10.1038/nrn3430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling, S.-C., Polymenidou, M. &amp; Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416&#x2013;438 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23931993</ArticleId><ArticleId IdType="pmc">4411085</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook, C., Zhang, Y.-J., Xu, Y., Dickson, D. W. &amp; Petrucelli, L. TDP-43 in neurodegenerative disorders. Expert Opin. Biol. Ther. 8, 969&#x2013;978 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18549326</ArticleId><ArticleId IdType="pmc">2855963</ArticleId><ArticleId IdType="doi">10.1517/14712598.8.7.969</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai, T. et al. Phosphorylated TDP-43 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol. 117, 125&#x2013;136 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19139911</ArticleId><ArticleId IdType="doi">10.1007/s00401-008-0480-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, J., Wang, L., Huntley, M. L., Perry, G. &amp; Wang, X. Pathomechanisms of TDP-43 in neurodegeneration. J. Neurochem. 146, 7&#x2013;20 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14327</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese, K. E. et al. TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with Lewy bodies and ageing. Brain Pathol. 27, 472&#x2013;479 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27495267</ArticleId><ArticleId IdType="doi">10.1111/bpa.12424</ArticleId></ArticleIdList></Reference><Reference><Citation>James, B. D. et al. TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain 139, 2983&#x2013;2993 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27694152</ArticleId><ArticleId IdType="pmc">5091047</ArticleId><ArticleId IdType="doi">10.1093/brain/aww224</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz, C. et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann. Neurol. 61, 435&#x2013;445 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17469117</ArticleId><ArticleId IdType="pmc">2677204</ArticleId><ArticleId IdType="doi">10.1002/ana.21154</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda, H. et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 114, 221&#x2013;229 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17653732</ArticleId><ArticleId IdType="doi">10.1007/s00401-007-0261-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi, S. et al. Concurrence of TDP-43, tau and &#x3b1;-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res. 1184, 284&#x2013;294 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17963732</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2007.09.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab, C., Arai, T., Hasegawa, M., Yu, S. &amp; McGeer, P. L. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J. Neuropathol. Exp. Neurol. 67, 1159&#x2013;1165 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19018245</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e31818e8951</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu, K. et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J. Neuropathol. Exp. Neurol. 67, 555&#x2013;564 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18520774</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e31817713b5</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda, T. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neuropathology 38, 72&#x2013;81 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28960544</ArticleId><ArticleId IdType="doi">10.1111/neup.12428</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti, E. &amp; Baralle, F. E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem. 276, 36337&#x2013;36343 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId><ArticleId IdType="doi">10.1074/jbc.M104236200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H. Y., Wang, I. F., Bose, J. &amp; Shen, C. K. J. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 83, 130&#x2013;139 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14667816</ArticleId><ArticleId IdType="doi">10.1016/S0888-7543(03)00214-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala, Y. M. et al. Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function. J. Mol. Biol. 348, 575&#x2013;588 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15826655</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2005.02.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou, M. et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 14, 459&#x2013;468 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21358643</ArticleId><ArticleId IdType="pmc">3094729</ArticleId><ArticleId IdType="doi">10.1038/nn.2779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, E. B., Lee, V. M.-Y. &amp; Trojanowski, J. Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13, 38&#x2013;50 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey, J. R. et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 14, 452&#x2013;458 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21358640</ArticleId><ArticleId IdType="pmc">3108889</ArticleId><ArticleId IdType="doi">10.1038/nn.2778</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti, E. et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 280, 37572&#x2013;37584 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16157593</ArticleId><ArticleId IdType="doi">10.1074/jbc.M505557200</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum, B. D., Chitta, R. K., High, A. A. &amp; Taylor, J. P. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J. Proteome Res. 9, 1104&#x2013;1120 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20020773</ArticleId><ArticleId IdType="pmc">2897173</ArticleId><ArticleId IdType="doi">10.1021/pr901076y</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini, M. et al. Role of selected mutations in the Q/N rich region of TDP-43 in EGFP-12xQ/N-induced aggregate formation. Brain Res. 1462, 139&#x2013;150 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22406069</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2012.02.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini, M. et al. Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J. Biol. Chem. 287, 7512&#x2013;7525 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22235134</ArticleId><ArticleId IdType="pmc">3293573</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111.288720</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman, M., Johnson, B. S., King, O. D., Gitler, A. D. &amp; Shorter, J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J. Cell Sci. 123, 1191&#x2013;1201 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20356930</ArticleId><ArticleId IdType="pmc">2848109</ArticleId><ArticleId IdType="doi">10.1242/jcs.051672</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuentealba, R. A. et al. Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J. Biol. Chem. 285, 26304&#x2013;26314 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20554523</ArticleId><ArticleId IdType="pmc">2924052</ArticleId><ArticleId IdType="doi">10.1074/jbc.M110.125039</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, L.-L. et al. Two mutations G335D and Q343R within the amyloidogenic core region of TDP-43 influence its aggregation and inclusion formation. Sci. Rep. 6, 23928 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27030292</ArticleId><ArticleId IdType="pmc">4814915</ArticleId><ArticleId IdType="doi">10.1038/srep23928</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt, H. B., Barreau, A. &amp; Rohatgi, R. Phase separation-deficient TDP43 remains functional in splicing. Nat. Commun. 10, 4890 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31653829</ArticleId><ArticleId IdType="pmc">6814767</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-12740-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompe&#xe1;n, M. et al. Structural characterization of the minimal segment of TDP-43 competent for aggregation. Arch. Biochem. Biophys. 545, 53&#x2013;62 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24440310</ArticleId><ArticleId IdType="doi">10.1016/j.abb.2014.01.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella, A. E., Zerze, G. H., Mittal, J. &amp; Fawzi, N. L. ALS mutations disrupt phase separation mediated by &#x3b1;-helical structure in the TDP-43 low-complexity C-terminal domain. Structure 24, 1537&#x2013;1549 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27545621</ArticleId><ArticleId IdType="pmc">5014597</ArticleId><ArticleId IdType="doi">10.1016/j.str.2016.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella, A. E. et al. TDP-43 &#x3b1;-helical structure tunes liquid&#x2013;liquid phase separation and function. Proc. Natl Acad. Sci. USA 117, 5883&#x2013;5894 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32132204</ArticleId><ArticleId IdType="pmc">7084079</ArticleId><ArticleId IdType="doi">10.1073/pnas.1912055117</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognesi, B. et al. The mutational landscape of a prion-like domain. Nat. Commun. 10, 4162 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31519910</ArticleId><ArticleId IdType="pmc">6744496</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-12101-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes, M. P. et al. Atomic structures of low-complexity protein segments reveal kinked &#x3b2; sheets that assemble networks. Science 359, 698&#x2013;701 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29439243</ArticleId><ArticleId IdType="pmc">6192703</ArticleId><ArticleId IdType="doi">10.1126/science.aan6398</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther, E. L. et al. Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation. Nat. Struct. Mol. Biol. 25, 463&#x2013;471 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29786080</ArticleId><ArticleId IdType="pmc">5990464</ArticleId><ArticleId IdType="doi">10.1038/s41594-018-0064-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther, E. L. et al. Atomic-level evidence for packing and positional amyloid polymorphism by segment from TDP-43 RRM2. Nat. Struct. Mol. Biol. 25, 311&#x2013;319 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29531287</ArticleId><ArticleId IdType="pmc">6056015</ArticleId><ArticleId IdType="doi">10.1038/s41594-018-0045-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya, M. R. et al. Atomic structures of amyloid cross-&#x3b2; spines reveal varied steric zippers. Nature 447, 453&#x2013;457 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId><ArticleId IdType="doi">10.1038/nature05695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. J. et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495, 467&#x2013;473 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23455423</ArticleId><ArticleId IdType="pmc">3756911</ArticleId><ArticleId IdType="doi">10.1038/nature11922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Q., Boyer, D. R., Sawaya, M. R., Ge, P. &amp; Eisenberg, D. S. Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nat. Struct. Mol. Biol. 26, 619&#x2013;627 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31235914</ArticleId><ArticleId IdType="pmc">7047951</ArticleId><ArticleId IdType="doi">10.1038/s41594-019-0248-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz, T. et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat. Commun. 8, 45 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28663553</ArticleId><ArticleId IdType="pmc">5491494</ArticleId><ArticleId IdType="doi">10.1038/s41467-017-00062-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercado, P. A., Ayala, Y. M., Romano, M., Buratti, E. &amp; Baralle, F. E. Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res. 33, 6000&#x2013;6010 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16254078</ArticleId><ArticleId IdType="pmc">1270946</ArticleId><ArticleId IdType="doi">10.1093/nar/gki897</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, J. et al. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: implications for the pathogenesis of tauopathies. J. Biol. Chem. 292, 10600&#x2013;10612 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28487370</ArticleId><ArticleId IdType="pmc">5481566</ArticleId><ArticleId IdType="doi">10.1074/jbc.M117.783498</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D. &amp; Crowther, R. A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron 3, 519&#x2013;526 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId><ArticleId IdType="doi">10.1016/0896-6273(89)90210-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulot, S. F. C., Hughes, K., Woodgett, J. R., Anderton, B. H. &amp; Hanger, D. P. PHF-tau from Alzheimer&#x2019;s brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3&#x3b2;. FEBS Lett. 349, 359&#x2013;364 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8050597</ArticleId><ArticleId IdType="doi">10.1016/0014-5793(94)00702-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, W.-K. et al. Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy. Ann. Neurol. 50, 494&#x2013;502 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11601500</ArticleId><ArticleId IdType="doi">10.1002/ana.1159</ArticleId></ArticleIdList></Reference><Reference><Citation>Takanashi, M., Mori, H., Arima, K., Mizuno, Y. &amp; Hattori, N. Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Mol. Brain Res. 104, 210&#x2013;219 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12225876</ArticleId><ArticleId IdType="doi">10.1016/S0169-328X(02)00382-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Umeda, Y. et al. Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies. Neurosci. Lett. 359, 151&#x2013;154 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15050686</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2004.01.060</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker, L. A. et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367&#x2013;371 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28405022</ArticleId><ArticleId IdType="pmc">5642042</ArticleId><ArticleId IdType="doi">10.1038/nature22038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling, S. C. et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc. Natl Acad. Sci. USA 107, 13318&#x2013;13323 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20624952</ArticleId><ArticleId IdType="pmc">2922163</ArticleId><ArticleId IdType="doi">10.1073/pnas.1008227107</ArticleId></ArticleIdList></Reference><Reference><Citation>Appocher, C. et al. Major hnRNP proteins act as general TDP-43 functional modifiers both in Drosophila and human neuronal cells. Nucleic Acids Res. 45, 8026&#x2013;8045 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28575377</ArticleId><ArticleId IdType="pmc">5570092</ArticleId><ArticleId IdType="doi">10.1093/nar/gkx477</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio, M. et al. Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc. Natl Acad. Sci. USA 109, 21510&#x2013;21515 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23236149</ArticleId><ArticleId IdType="pmc">3535614</ArticleId><ArticleId IdType="doi">10.1073/pnas.1211577110</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga, A. et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS ONE 7, e43120 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22900096</ArticleId><ArticleId IdType="pmc">3416794</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0043120</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshaies, J.-E. et al. TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. Brain 141, 1320&#x2013;1333 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29562314</ArticleId><ArticleId IdType="pmc">5917749</ArticleId><ArticleId IdType="doi">10.1093/brain/awy062</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ambrogio, A. et al. Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res. 37, 4116&#x2013;4126 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19429692</ArticleId><ArticleId IdType="pmc">2709582</ArticleId><ArticleId IdType="doi">10.1093/nar/gkp342</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao, S. et al. RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. Mol. Cell. Neurosci. 47, 167&#x2013;180 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21421050</ArticleId><ArticleId IdType="doi">10.1016/j.mcn.2011.02.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj, A., Myers, M. P., Buratti, E. &amp; Baralle, F. E. Characterizing TDP-43 interaction with its RNA targets. Nucleic Acids Res. 41, 5062&#x2013;5074 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23519609</ArticleId><ArticleId IdType="pmc">3643599</ArticleId><ArticleId IdType="doi">10.1093/nar/gkt189</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan, Z., Chen, X. &amp; Chen, R. Transcriptome-wide analysis of TDP-43 binding small RNAs identifies miR-NID1 (miR-8485), a novel miRNA that represses NRXN1 expression. Genomics 103, 76&#x2013;82 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23827811</ArticleId><ArticleId IdType="doi">10.1016/j.ygeno.2013.06.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapeli, K. et al. Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses. Nat. Commun. 7, 12143 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27378374</ArticleId><ArticleId IdType="pmc">4935974</ArticleId><ArticleId IdType="doi">10.1038/ncomms12143</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta, P. et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 37, e98684 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29764981</ArticleId><ArticleId IdType="pmc">5983119</ArticleId><ArticleId IdType="doi">10.15252/embj.201798684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling, J. P., Pletnikova, O., Troncoso, J. C. &amp; Wong, P. C. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650&#x2013;655 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26250685</ArticleId><ArticleId IdType="pmc">4825810</ArticleId><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, Q. et al. Extensive cryptic splicing upon loss of RBM17 and TDP43 in neurodegeneration models. Hum. Mol. Genet. 25, 5083&#x2013;5093 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">28007900</ArticleId><ArticleId IdType="pmc">5968355</ArticleId></ArticleIdList></Reference><Reference><Citation>Rot, G. et al. High-resolution RNA maps suggest common principles of splicing and polyadenylation regulation by TDP-43. Cell Rep. 19, 1056&#x2013;1067 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28467899</ArticleId><ArticleId IdType="pmc">5437728</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.04.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed, Z. et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 22, 180&#x2013;190 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30643298</ArticleId><ArticleId IdType="pmc">6348009</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim, J. R. et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 22, 167&#x2013;179 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30643292</ArticleId><ArticleId IdType="pmc">7153761</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio, M. et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J. Clin. Invest. 130, 6080&#x2013;6092 (2020). Together with Melamed et al. (2019) and Klim et al. (2019), this paper identifies and describes TDP43-mediated regulation of stathmin-2 by TDP43 and its disease-related deregulation as a defining feature of ALS and FTD.</Citation><ArticleIdList><ArticleId IdType="pubmed">32790644</ArticleId><ArticleId IdType="pmc">7598060</ArticleId><ArticleId IdType="doi">10.1172/JCI139741</ArticleId></ArticleIdList></Reference><Reference><Citation>White, M. A. et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 21, 552&#x2013;563 (2018). This study introduces a single amino acid change in mouse TDP43 mimicking ALS-related mutant Q331K that affects the 3D structure and function of its low-complexity domain, thereby uncovering a direct relation to defective autoregulation.</Citation><ArticleIdList><ArticleId IdType="pubmed">29556029</ArticleId><ArticleId IdType="pmc">5884423</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, B. S., McCaffery, J. M., Lindquist, S. &amp; Gitler, A. D. A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA 105, 6439&#x2013;6444 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18434538</ArticleId><ArticleId IdType="pmc">2359814</ArticleId><ArticleId IdType="doi">10.1073/pnas.0802082105</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. et al. A Drosophila model for TDP-43 proteinopathy. Proc. Natl Acad. Sci. USA 107, 3169&#x2013;3174 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20133767</ArticleId><ArticleId IdType="pmc">2840283</ArticleId><ArticleId IdType="doi">10.1073/pnas.0913602107</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaper, D. C. et al. Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum. Mol. Genet. 22, 1539&#x2013;1557 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23307927</ArticleId><ArticleId IdType="pmc">3605831</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddt005</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid, B. et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc. Natl Acad. Sci. USA 110, 4986&#x2013;4991 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23457265</ArticleId><ArticleId IdType="pmc">3612625</ArticleId><ArticleId IdType="doi">10.1073/pnas.1218311110</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils, H. et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 107, 3858&#x2013;3863 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20133711</ArticleId><ArticleId IdType="pmc">2840518</ArticleId><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M. &amp; Baloh, R. H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 106, 18809&#x2013;18814 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19833869</ArticleId><ArticleId IdType="pmc">2762420</ArticleId><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup, V. et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 134, 2610&#x2013;2626 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21752789</ArticleId><ArticleId IdType="doi">10.1093/brain/awr159</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayton, R. D. et al. Selective forelimb impairment in rats expressing a pathological TDP-43 25 kDa C-terminal fragment to mimic amyotrophic lateral sclerosis. Mol. Ther. 21, 1324&#x2013;1334 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23689600</ArticleId><ArticleId IdType="pmc">3702099</ArticleId><ArticleId IdType="doi">10.1038/mt.2013.88</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida, A. et al. Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. Brain 135, 833&#x2013;846 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22252998</ArticleId><ArticleId IdType="pmc">3286326</ArticleId><ArticleId IdType="doi">10.1093/brain/awr348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala, Y. M. et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 30, 277&#x2013;288 (2011). This study was the first to report that autoregulation of TDP43 is a mechanism to regulate its expression level and localization.</Citation><ArticleIdList><ArticleId IdType="pubmed">21131904</ArticleId><ArticleId IdType="doi">10.1038/emboj.2010.310</ArticleId></ArticleIdList></Reference><Reference><Citation>Avenda&#xf1;o-V&#xe1;zquez, S. E. et al. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev. 26, 1679&#x2013;1684 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22855830</ArticleId><ArticleId IdType="pmc">3418585</ArticleId><ArticleId IdType="doi">10.1101/gad.194829.112</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama, A. et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 44, 5820&#x2013;5836 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27257061</ArticleId><ArticleId IdType="pmc">4937342</ArticleId><ArticleId IdType="doi">10.1093/nar/gkw499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bembich, S. et al. Predominance of spliceosomal complex formation over polyadenylation site selection in TDP-43 autoregulation. Nucleic Acids Res. 42, 3362&#x2013;3371 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24369426</ArticleId><ArticleId IdType="doi">10.1093/nar/gkt1343</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons, M. et al. Splicing factors act as genetic modulators of TDP-43 production in a new autoregulatory TDP-43 Drosophila model. Hum. Mol. Genet. 26, 3396&#x2013;3408 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28854702</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddx229</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alton, S., Altshuler, M. &amp; Lewis, J. Studies of alternative isoforms provide insight into TDP-43 autoregulation and pathogenesis. RNA 21, 1419&#x2013;1432 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26089325</ArticleId><ArticleId IdType="pmc">4509932</ArticleId><ArticleId IdType="doi">10.1261/rna.047647.114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugai, A. et al. Non-genetically modified models exhibit TARDBP mRNA increase due to perturbed TDP-43 autoregulation. Neurobiol. Dis. 130, 104534 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31310801</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2019.104534</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores, B. N. et al. An intramolecular salt bridge linking TDP43 RNA binding, protein stability, and TDP43-dependent neurodegeneration. Cell Rep. 27, 1133&#x2013;1150.e8 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31018129</ArticleId><ArticleId IdType="pmc">6499398</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2019.03.093</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp, K. et al. Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. J. Clin. Invest. 130, 1139&#x2013;1155 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31714900</ArticleId><ArticleId IdType="pmc">7269575</ArticleId><ArticleId IdType="doi">10.1172/JCI130988</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho, M. A. et al. TARDBP 3&#x2032;-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol. 118, 633&#x2013;645 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19618195</ArticleId><ArticleId IdType="pmc">2783457</ArticleId><ArticleId IdType="doi">10.1007/s00401-009-0571-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. M. et al. TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Brain Commun. 1, fcz014 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31633109</ArticleId><ArticleId IdType="pmc">6788139</ArticleId><ArticleId IdType="doi">10.1093/braincomms/fcz014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chook, Y. M. &amp; Blobel, G. Karyopherins and nuclear import. Curr. Opin. Struct. Biol. 11, 703&#x2013;715 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11751052</ArticleId><ArticleId IdType="doi">10.1016/S0959-440X(01)00264-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Prpar Mihevc, S. et al. Nuclear trafficking in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Brain 140, 13&#x2013;26 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27497493</ArticleId><ArticleId IdType="doi">10.1093/brain/aww197</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura, A. L. et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 133, 1763&#x2013;1771 (2010). This study was the first to show direct interactions between TDP43 and karyopherins, alterations of which characterize ALS and FTD.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId><ArticleId IdType="doi">10.1093/brain/awq111</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton, M. J. et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 283, 13302&#x2013;13309 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18305110</ArticleId><ArticleId IdType="pmc">2442318</ArticleId><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle, H. et al. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci. Rep. 8, 7084 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29728564</ArticleId><ArticleId IdType="pmc">5935713</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-25007-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy, R. &amp; Wente, S. R. An RNA-export mediator with an essential nuclear export signal. Nature 383, 357&#x2013;360 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8848052</ArticleId><ArticleId IdType="doi">10.1038/383357a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle, H. &amp; Dormann, D. TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett. 591, 1489&#x2013;1507 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28380257</ArticleId><ArticleId IdType="doi">10.1002/1873-3468.12646</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkmann, A. W., Dawson, T. R. &amp; Wente, S. R. Insights into mRNA export-linked molecular mechanisms of human disease through a Gle1 structure&#x2013;function analysis. Adv. Biol. Regul. 54, 74&#x2013;91 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24275432</ArticleId><ArticleId IdType="doi">10.1016/j.jbior.2013.10.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb, H. M. et al. Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Hum. Mol. Genet. 24, 1363&#x2013;1373 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25343993</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddu545</ArticleId></ArticleIdList></Reference><Reference><Citation>Aditi, Glass, L., Dawson, T. R. &amp; Wente, S. R. An amyotrophic lateral sclerosis-linked mutation in GLE1 alters the cellular pool of human Gle1 functional isoforms. Adv. Biol. Regul. 62, 25&#x2013;36 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26776475</ArticleId><ArticleId IdType="doi">10.1016/j.jbior.2015.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson, A. et al. Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies. Acta Neuropathol. Commun. 7, 65 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31036086</ArticleId><ArticleId IdType="pmc">6487524</ArticleId><ArticleId IdType="doi">10.1186/s40478-019-0710-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi, E. S. et al. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci. Rep. 8, 7083 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29728608</ArticleId><ArticleId IdType="pmc">5935693</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-25008-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold, H. C. et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci. Rep. 8, 4606 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29545601</ArticleId><ArticleId IdType="pmc">5854632</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-22858-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickramasinghe, V. O. &amp; Laskey, R. A. Control of mammalian gene expression by selective mRNA export. Nat. Rev. Mol. Cell Biol. 16, 431&#x2013;442 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26081607</ArticleId><ArticleId IdType="doi">10.1038/nrm4010</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz, L. M. et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 121, 726&#x2013;738 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21206091</ArticleId><ArticleId IdType="pmc">3026736</ArticleId><ArticleId IdType="doi">10.1172/JCI44867</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker, A. K. et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 130, 643&#x2013;660 (2015). This study shows that the reversible expression of human TARDBP carrying a deletion of the TDP43 NLS in mice results in accumulation of cytoplasmic aggregates and loss of nuclear TDP43, leading to neurodegeneration and motor dysfunction. The subsequent removal of cytoplasmic TDP43 and return of nuclear TDP43 lead to neuron preservation, muscle reinnervation and functional recovery.</Citation><ArticleIdList><ArticleId IdType="pubmed">26197969</ArticleId><ArticleId IdType="pmc">5127391</ArticleId><ArticleId IdType="doi">10.1007/s00401-015-1460-x</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId><ArticleId IdType="pmc">3202986</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21944779</ArticleId><ArticleId IdType="pmc">3200438</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaber, J. &amp; Talbot, K. What is the role of TDP-43 in C9orf72-related amyotrophic lateral sclerosis and frontemporal dementia? Brain 139, 3057&#x2013;3059 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27913405</ArticleId><ArticleId IdType="doi">10.1093/brain/aww264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori, K. et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId><ArticleId IdType="doi">10.1126/science.1232927</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, K. et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26308891</ArticleId><ArticleId IdType="pmc">4800742</ArticleId><ArticleId IdType="doi">10.1038/nature14973</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum, B. D. et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525, 129&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26308899</ArticleId><ArticleId IdType="pmc">4631399</ArticleId><ArticleId IdType="doi">10.1038/nature14974</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107;, A. et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 18, 1226&#x2013;1229 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26308983</ArticleId><ArticleId IdType="pmc">4552077</ArticleId><ArticleId IdType="doi">10.1038/nn.4085</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, K. H. et al. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell 167, 774&#x2013;788 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27768896</ArticleId><ArticleId IdType="pmc">5079111</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.10.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems, S., Bogaert, E., Van Damme, P. &amp; Van Den Bosch, L. Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol. 132, 159&#x2013;173 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27271576</ArticleId><ArticleId IdType="pmc">4947127</ArticleId><ArticleId IdType="doi">10.1007/s00401-016-1586-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems, S. et al. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci. Rep. 6, 20877 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26869068</ArticleId><ArticleId IdType="pmc">4751451</ArticleId><ArticleId IdType="doi">10.1038/srep20877</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou, C.-C. et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci. 21, 228&#x2013;239 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29311743</ArticleId><ArticleId IdType="pmc">5800968</ArticleId><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon, D. A. et al. A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-&#x3b1; mediates C9orf72-related neurodegeneration. Brain 141, 2908&#x2013;2924 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30239641</ArticleId><ArticleId IdType="pmc">6158706</ArticleId><ArticleId IdType="doi">10.1093/brain/awy241</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak, W. M. et al. The role of liquid&#x2013;liquid phase separation in aggregation of the TDP-43 low-complexity domain. J. Biol. Chem. 294, 6306&#x2013;6317 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30814253</ArticleId><ArticleId IdType="pmc">6484124</ArticleId><ArticleId IdType="doi">10.1074/jbc.RA118.007222</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems, S. et al. Protein phase separation: a new phase in cell biology. Trends Cell Biol. 28, 420&#x2013;435 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29602697</ArticleId><ArticleId IdType="pmc">6034118</ArticleId><ArticleId IdType="doi">10.1016/j.tcb.2018.02.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti, S. &amp; Hyman, A. A. Are aberrant phase transitions a driver of cellular aging? BioEssays 38, 959&#x2013;968 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27554449</ArticleId><ArticleId IdType="pmc">5108435</ArticleId><ArticleId IdType="doi">10.1002/bies.201600042</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, Y. &amp; Brangwynne, C. P. Liquid phase condensation in cell physiology and disease. Science 357, 4382 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf4382</ArticleId></ArticleIdList></Reference><Reference><Citation>French, R. L. et al. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J. Biol. Chem. 294, 6696&#x2013;6709 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30824544</ArticleId><ArticleId IdType="pmc">6497947</ArticleId><ArticleId IdType="doi">10.1074/jbc.RA118.005889</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, L. et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell 173, 677&#x2013;692 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29677512</ArticleId><ArticleId IdType="pmc">5911940</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2018.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa, F. et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron 102, 339&#x2013;357 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30853299</ArticleId><ArticleId IdType="pmc">6548321</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann, J. R. et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron 102, 321&#x2013;338.e8 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30826182</ArticleId><ArticleId IdType="pmc">6472983</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.01.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopal, P. P., Nirschl, J. J., Klinman, E. &amp; Holzbaur, E. L. F. Amyotrophic lateral sclerosis-linked mutations increase the viscosity of liquid-like TDP-43 RNP granules in neurons. Proc. Natl Acad. Sci. USA 114, E2466&#x2013;E2475 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28265061</ArticleId><ArticleId IdType="pmc">5373408</ArticleId><ArticleId IdType="doi">10.1073/pnas.1614462114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, A. et al. A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. EMBO J. 37, e97452 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29438978</ArticleId><ArticleId IdType="pmc">5830921</ArticleId><ArticleId IdType="doi">10.15252/embj.201797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex, A. et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell 163, 123&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26406374</ArticleId><ArticleId IdType="pmc">5149108</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2015.09.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, H. R., Chiang, W. C., Chou, P. C., Wang, W. J. &amp; Huang, J. R. TAR DNA-binding protein 43 (TDP-43) liquid&#x2013;liquid phase separation is mediated by just a few aromatic residues. J. Biol. Chem. 293, 6090&#x2013;6098 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29511089</ArticleId><ArticleId IdType="pmc">5912450</ArticleId><ArticleId IdType="doi">10.1074/jbc.AC117.001037</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker, M. &amp; Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45&#x2013;51 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24005412</ArticleId><ArticleId IdType="pmc">3963807</ArticleId><ArticleId IdType="doi">10.1038/nature12481</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider, J. et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74, 20&#x2013;38 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23686809</ArticleId><ArticleId IdType="pmc">3785076</ArticleId><ArticleId IdType="doi">10.1002/ana.23937</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider, J. et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 127, 423&#x2013;439 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24407427</ArticleId><ArticleId IdType="pmc">3971993</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1238-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami, I., Arai, T. &amp; Hasegawa, M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. 138, 751&#x2013;770 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31555895</ArticleId><ArticleId IdType="pmc">6800885</ArticleId><ArticleId IdType="doi">10.1007/s00401-019-02077-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber, M. et al. Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell 173, 706&#x2013;719.e13 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29677514</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2018.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerner, A. C. et al. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science 351, 173&#x2013;176 (2016). This study shows, using cell culture models, that cytoplasmic accumulation of TDP43 fragments causes the sequestration and mislocalization of proteins containing disordered and low-complexity domains. These include multiple factors involved in the nuclear import and export machinery, leading to impaired nucleocytoplasmic transport.</Citation><ArticleIdList><ArticleId IdType="pubmed">26634439</ArticleId><ArticleId IdType="doi">10.1126/science.aad2033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosyna, F. K. &amp; Depping, R. Controlling the gatekeeper: therapeutic targeting of nuclear transport. Cells 7, 221 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">6262578</ArticleId><ArticleId IdType="doi">10.3390/cells7110221</ArticleId></ArticleIdList></Reference><Reference><Citation>Haines, J. D. et al. Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination. Nat. Neurosci. 18, 511&#x2013;520 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25706475</ArticleId><ArticleId IdType="pmc">4522902</ArticleId><ArticleId IdType="doi">10.1038/nn.3953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa, M. et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 64, 60&#x2013;70 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18546284</ArticleId><ArticleId IdType="pmc">2674108</ArticleId><ArticleId IdType="doi">10.1002/ana.21425</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann, M. et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 117, 137&#x2013;149 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19125255</ArticleId><ArticleId IdType="pmc">2693625</ArticleId><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>